Renal Ex Vivo SYN002 Perfusion to Eliminate CMV Transmission
Key facts
- Where
- Toronto, CanadaSee the site
- Phase
- Early phase 1
Where in Canada
- University Health Network, Toronto General Hospital, Ajmera Transplant CentreToronto, CanadaContact: Ilona Bahinskaya, MSc, CCRPNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Health Network, Toronto
- Trial code
- NCT07488481
- Record updated
- 23 March 2026
- Original description
Donor organs often carry latent Cytomegalovirus (CMV) infection that may be transmitted to the recipient. The goal of this clinical trial is to determine the safety of SYN002 treatment during Ex-Vivo Organ Perfusion (EVOP) in clinical kidney transplantation. Donor kidneys will be treated on the EVOP system with SYN002 in order to decrease the burden of latent CMV in the organ and mitigate the transmission of cytomegalovirus (CMV).Read full original descriptionShow less
Renal Ex Vivo SYN002 Perfusion to Eliminate CMV Transmission: A Safety Trial in Kidney Transplant Recipients
Donor organs often carry latent Cytomegalovirus (CMV) infection that may be transmitted to the recipient. The goal of this clinical trial is to determine the safety of SYN002 treatment during Ex-Vivo Organ Perfusion (EVOP) in clinical kidney transplantation. Donor kidneys will be treated on the EVOP system with SYN002 in order to decrease the burden of latent CMV in the organ and mitigate the transmission of cytomegalovirus (CMV).
Recipient Inclusion Criteria:; Age ≥18 years; Listed for kidney transplantation; Either CMV seronegative or seropositive; Willing to provide written informed consent to take part in the trial; Willing and able to return for follow-up visits as scheduled in the protocol; Not participating in other interventional trials; Recipient Exclusion Criteria:; Listed for combined organ transplant (e.g. kidney-pancreas or kidney-liver); Re-transplantation; HIV positive; Highly sensitized recipient with a PRA >=95; Planned use of belatacept or alemtuzumab immunosuppression (both non-approved drugs in Canada); Unable or unwilling to comply with study procedures; Donor Inclusion Criteria:; Deceased donor; CMV seropositive (D+); Donor kidney meets criteria for transplantation; Single renal artery (required anatomy to perform EVOP); Donor Exclusion Criteria:; CMV seronegative; Donor kidney not suitable for transplantation.